Question

A 51-year-old woman with HFrEF (EF 32%) on ARNI, beta-blocker, and MRA remains symptomatic. eGFR 62 mL/min/1.73 m², potassium 4.5 mEq/L, A1C 6.1%. Which addition provides morbidity/mortality benefit independent of diabetes status?

Accepted Answer

SGLT2 inhibitor

Answer

DPP-4 inhibitor

Answer

Thiazolidinedione

Answer

Nondihydropyridine CCB

Answer

Nitrate monotherapy

Practice question

A 51-year-old woman with HFrEF (EF 32%) on ARNI, beta-blocker, and MRA remains symptomatic. eGFR 62 mL/min/1.73 m², potassium 4.5 mEq/L, A1C 6.1%. Which addition provides morbidity/mortality benefit independent of diabetes status?